DAILY PROGRAM
Standard Time: GMT +09:00, Seoul/Tokyo
ROOM A
08:00-08:50
Plenary Session II
Kye Young Lee (Konkuk Univ.)
08:00-08:50
Overcoming Resistance to Immune-Targeted Therapies
Fabrice Barlesi (Gustave Roussy, France)
08:50-09:50
Session V (A) Recent Advances in Diagnostic and Interventional Bronchoscopy
Bin Hwangbo (National Cancer Center)
08:50-09:10
Radial EBUS Guided TBLB for Peripheral Pulmonary Lesions
June Hong Ahn (Yeungnam Univ.)
09:10-09:30
ENB-Guided Preoperative Localization for Small Pulmonary Nodules
In Kyu Park (Seoul National Univ.)
09:30-09:50
ENB-Guided Ablative Therapy
Calvin S. H. NG (The Chinese Univ. of Hong Kong, Hong Kong)
09:50-10:10
Coffee Break
10:10-11:25
Session VI (A) Oral Presentation II
Hee Kyung Ahn (Gachon Univ.)
10:10-10:19
A Prospective Phase 2 Study of Rapid Detection and EGFR-TKI Initiation by EV-Based BALF Liquid Biopsy in Advanced NSCLC Patients
In Ae Kim (Konkuk University)
10:19-10:28
Overall Survival with Afatinib as First-Line Therapy for Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in KATRD EGFR Cohort
Sung Yong Lee (Korea University )
10:28-10:37
Efficacy and Safety of Lazertinib 240 mg in Patients with EGFR T790M Mutant NSCLC: Data from a Phase I/II Study
Byoung Chul Cho (Yonsei University)
10:37-10:46
Sequential Afatinib and Osimertinib in Asians with EGFR Mutation-Positive NSCLC and T790M-Mediated Acquired Resistance: Combined Analysis of Two Non-Interventional Studies
Hyun Ae Jung (Sungkyunkwan University)
10:46-10:55
High Tumor Mutation Burden Predicts Unfavorable Clinical Outcomes in EGFR-Mutated Lung Adenocarcinoma Treated with Targeted Therapy
Seung Hyeun Lee (Kyung Hee University)
10:55-11:04
Combination Osimertinib Plus Selpercatinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET Fusions
Ari Jeon (Eli Lilly and Company)
11:04-11:13
Effect of N-acetylcysteine on Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients
Jun Hyeok Lim (Inha University)
11:13-11:22
Efficacy and Safety of Selpercatinib (LOXO-292) in East-Asian Patients with RET Fusion-Positive NSCLC
Se Hoon Lee (Sungkyunkwan University)
11:25-12:10
Satellite Symposium IV [Pfizer]
Jin Seok Ahn (Sungkyunkwan Univ.)
11:25-12:10
Lorlatinib: Clinical Data and Implications for the Sequential Therapy in Anaplastic Lymphoma Kinase+Non-Small Cell Lung Cancer
Benjamin Solomon (Peter MacCallum Cancer Centre, Australia)
12:10-13:00
Lunch Break
13:00-14:40
Session VII (A) Oral Presentation III
In Kyu Park (Seoul National Univ.)
13:00-13:09
Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated with Neoadjuvant CCRT Followed by Surgery
Sehhoon Park (Sungkyunkwan University)
13:09-13:18
Vision Artificial Intelligence Factor in Image Registration for Lung Stereotactic Body Radiotherapy
Kaile Li (Varian Medical System)
13:18-13:27
Phase 1 Trial Evaluating Safety of the Macrophage Target Sentinel Lymph Node Tracer (99mTc-MSA) Combined with Indocyanine Green for Intraoperative Sentinel Lymph Nodes Detection in Lung Cancer Surgery
Jun Hee Lee (Korea University)
13:27-13:36
Treatment Outcomes of Re-Irradiation Using Stereotactic Ablative Radiotherapy to Lung: A Propensity Score Matching Analysis
Tae Hoon Lee (Seoul National University)
13:36-13:45
Consolidative High-Dose Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer in Korea
Juwhan Choi (Korea University)
13:45-13:54
A Propensity-Matched Real-world Data Analysis of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
Cheol-Kyu Park (Chonnam National University )
13:54-14:03
Low-Level Expression of Necroptosis Factors Indicates a Poor Prognosis of the Squamous Cell Carcinoma Subtype of Non-Small-Cell Lung Cancer
Jun Hyeok Lim (Inha University )
14:03-14:12
Prognostic Significance of Extracapsular Extension in Patients with Pathologic N1 Non-Small Cell Lung Cancer Undergoing Complete Resection
Jae Kwang Yun (University of Ulsan)
14:12-14:21
Optimization of Indocyanine Green for Intraoperative Fluorescence Image-guided Thoracoscopic Resection of Lung Cancer
Yu Hua Quan (Korea University)
14:21-14:30
Radiotherapy for Resected Non-Small Cell Lung Cancer in Elderly Patients
Yoon Young Jo (University of Ulsan)
14:30-14:39
Is Moderate-Intensity Stereotactic Body Radiation Therapy Feasible for Ultra-Central Lung Cancer?: Updated Results
Chai Hong Rim (Korea University)
14:40-15:00
Coffee Break
15:00-16:40
Session VIII (A) Perspectives on Immuno-Oncology
Sang-We Kim (Univ. of Ulsan)
15:00-15:25
Predictive Biomarkers to Immune Checkpoint Blockade
Hye Ryun Kim (Yonsei Univ.)
15:25-15:50
Resistance Mechanisms to Immune Checkpoint Blockade
Se-Hoon Lee (Sungkyunkwan Univ.)
15:50-16:15
Novel Immune Checkpoint Blockade
Sehhoon Park (Sungkyunkwan Univ.)
16:15-16:40
Immunotherapy Beyond Immune Checkpoint Blockade
Ross Soo (National Univ. Cancer Institute, Singapore)
16:40-16:50
Coffee Break
16:50-17:40
Satellite Symposium VI [AstraZeneca]
Sei-Hoon Yang (Wonkwang Univ.)
16:50-17:40
Shifting Paradigm in EGFRm Non-Small Cell Lung Cancer Treatment from Advanced to Early Stage Patients
Terufumi Kato (Kanagawa Cancer Center, Japan)
17:40-17:50
Closing
ROOM B
08:50-09:50
Session V (B) Imaging the Lymphatic System in Lung Cancer
Jin-Hwan Kim (Chungnam National Univ.)
08:50-09:10
Lymphatic Pathways of the Thorax: Predictable Patterns of Spread of Non-Small Cell Lung Cancer
Jae Hyun Jeon (Seoul National Univ.)
09:10-09:30
MR Lymphangiography: Current Experiences Focusing on Lung Cancer
Hyun Jung Koo (Univ. of Ulsan)
09:30-09:50
Integrated LN Imaging for Lung Cancer Including CT, PET, and MRI: Update
Ho Yun Lee (Sungkyunkwan Univ.)
09:50-10:10
Coffee Break
10:10-11:25
Session VI (B) Proper Approach to Oligometastasis
Hong-Gyun Wu (Seoul National Univ.)
10:10-10:35
How to Handle Oligometastatic Disease in Non-Small Cell Lung Cancer
Hauke Winter (Universitätsklinikum Heidelberg, Germany)
10:35-11:00
Surgical Role in Oligometastasis to the Spines
Seung-Jae Hyun (Seoul National Univ.)
11:00-11:25
Local Ablative Therapy with Radiation in Extra-Thoracic Visceral Oligometastasis
Jin Ho Kim (Seoul National Univ.)
11:25-12:10
Satellite Symposium V [Yuhan]
Taewon Jang (Kosin Univ.)
11:25-12:10
A New Era in the Treatment of EGFR Mutation: LECLAZA®
Jin Hyoung Kang (The Catholic Univ. of Korea )
12:10-13:00
Lunch Break
13:00-14:40
Session VII (B) KALC-KAI Joint Symposium: Combination Immunotherapy Turning Cold into Hot
Kyung-Mi Lee (Korea Univ.), In-Jae Oh (Chonnam National Univ.)
13:00-13:25
Oligometastasis with Radiotherapy and Immunotherapy
To Be Confirmed
13:25-13:50
Integrating Metabolism with Systems Immunology in Immunity and Cancer
Hongbo Chi (St. Jude Children's Research Hospital, USA)
13:50-14:15
Cold to Hot Conversion
In-San Kim (KIST)
14:15-14:40
How Can We Enhance the Treatment Responses of Anti-PD-1 in Cancers?
Su-Hyung Park (KAIST)
14:40-15:00
Coffee Break
15:00-16:40
Session VIII (B) Translational Research
Geon Kook Lee (National Cancer Center)
15:00-15:25
Organoid Models for Lung Cancer Research
Se JIn Jang (Univ. of Ulsan)
15:25-15:50
Identification and Validation of Effective Cancer Neoantigens
Jung Kyoon Choi (KAIST)
15:50-16:15
Interpatient and Intratumor Heterogeneity of Drug Distribution
Maurizio D'Incalci (Humanitas Research Hospital, Italy)
16:15-16:40
Development and Preclinical Evaluation of Immuno-Oncology Drugs
Seung-Oe Lim (Purdue Univ., USA)